サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：細胞・遺伝子治療CDMOの世界市場：産業分析、規模、シェア、成長、動向、予測（2024～2032年）
市場調査レポート
商品コード
1408978

細胞・遺伝子治療CDMOの世界市場：産業分析、規模、シェア、成長、動向、予測（2024～2032年）

Global Cell And Gene Therapy CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 242 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
細胞・遺伝子治療CDMOの世界市場：産業分析、規模、シェア、成長、動向、予測（2024～2032年）
出版日: 2024年01月01日
発行: Value Market Research
ページ情報: 英文 242 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の細胞・遺伝子治療CDMOの市場規模は、2022年に40億5,000万米ドルに達し、2023～2030年の予測期間中にCAGR 28.11%で成長し、2030年には293億9,000万米ドルに達すると予測されています。

細胞・遺伝子治療開発製造受託機関（CDMO）は、他のバイオ医薬品企業に代わって細胞・遺伝子治療の開発、製造、試験のサービスを提供する専門企業です。細胞療法や遺伝子療法は、患者の細胞を操作・工学的に操作し、病気の治療や予防を行う先進的な治療法です。これらの治療法は、特定のがん、遺伝性疾患、その他の重篤な疾患など、様々な症状に対して大きな可能性を秘めています。

市場力学

細胞・遺伝子治療開発製造受託機関（CDMO）市場は、複数の要因によって大きな成長を遂げています。様々な疾患に対する革新的な治療法として細胞・遺伝子治療への注目と投資の高まりが、専門的な製造サービスへの需要を後押ししています。これらの治療に関わる製造工程の複雑さと、専門知識や専門施設の必要性が、CDMOへのアウトソーシング傾向の高まりにつながっています。薬事サポートとコンプライアンスは重要な推進力であり、細胞・遺伝子治療に対する厳しい薬事要件により、基準遵守の実績がある経験豊富なCDMOが強く求められています。CDMOが提供する柔軟性と拡張性は、バイオ製薬企業が臨床試験の進捗や商業化のニーズに効果的に生産体制を適応させることを可能にし、市場に影響を与える重要な要因です。細胞治療と遺伝子治療の分野が進歩するにつれ、CDMOサービスの需要は引き続き拡大すると予想され、これらの組織は革新的な治療法の開発と製造をサポートする上で重要な役割を果たしています。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、細胞・遺伝子治療CDMOの世界市場における各セグメントを包括的に評価することもできます。細胞・遺伝子治療CDMO産業の成長と動向は、この研究に全体的なアプローチを提供します。

地域分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける細胞・遺伝子治療CDMO市場の現在と将来の需要を強調する地域展望をカバーします。さらに、本レポートでは、すべての主要地域における個々の用途セグメントの需要、推定・予測に焦点を当てています。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場ハイライト
  • 世界市場スナップショット

第3章 細胞・遺伝子治療CDMO - 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 細胞・遺伝子治療CDMOの世界市場分析：フェーズ別

  • 概要：フェーズ別
  • 実績データと予測データ
  • 分析：フェーズ別
  • 前臨床
  • 臨床

第6章 細胞・遺伝子治療CDMOの世界市場分析：製品タイプ別

  • 概要：製品タイプ別
  • 実績データと予測データ
  • 分析：製品タイプ別
  • 遺伝子治療
  • 遺伝子改変細胞療法
  • 細胞療法

第7章 細胞・遺伝子治療CDMOの世界市場分析：適応症別

  • 概要：適応症別
  • 実績データと予測データ
  • 分析：適応症別
  • がん
  • 感染症
  • 神経疾患
  • 希少疾患
  • その他

第8章 細胞・遺伝子治療CDMOの世界市場分析：地域別

  • 展望：地域別
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第9章 細胞・遺伝子治療CDMO企業の競合情勢

  • 細胞・遺伝子治療CDMO市場競争
  • 提携・協力・合意
  • 合併・買収
  • 新製品上市
  • その他の開発

第10章 企業プロファイル

  • 企業シェア分析
  • 市場集中度
  • Lonza
  • Catalent Inc
  • Cytiva
  • Samsung Biologics
  • Thermo Fisher Scientific Inc.
  • Novartis AG
  • WuXi AppTec
  • AGC Biologics
  • OmniaBio
  • Rentschler Biopharma SE
  • Charles River Laboratories
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Phase (USD MN)
  • Pre-clinical Market Sales by Geography (USD MN)
  • Clinical Market Sales by Geography (USD MN)
  • Analysis Market by Product Type (USD MN)
  • Gene Therapy (Ex-vivo, In-vivo) Market Sales by Geography (USD MN)
  • Gene-Modified Cell Therapy (CAR T-cell Therapies, CAR-NK Cell Therapy, TCR-T Cell Therapy, Other) Market Sales by Geography (USD MN)
  • Cell Therapy Market Sales by Geography (USD MN)
  • Analysis by Indication (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Infectious Diseases Market Sales by Geography (USD MN)
  • Neurological Disorders Market Sales by Geography (USD MN)
  • Rare Diseases Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Cell And Gene Therapy Cdmo Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Cell And Gene Therapy Cdmo Report
  • Market Research Process
  • Market Research Methodology
  • Global Cell And Gene Therapy Cdmo Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Phase
  • Market Attractiveness Analysis by Product Type
  • Market Attractiveness Analysis by Indication
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Phase (USD MN)
  • Pre-clinical Market Sales by Geography (USD MN)
  • Clinical Market Sales by Geography (USD MN)
  • Global Market Analysis by Product Type (USD MN)
  • Gene Therapy (Ex-vivo, In-vivo) Market Sales by Geography (USD MN)
  • Gene-Modified Cell Therapy (CAR T-cell Therapies, CAR-NK Cell Therapy, TCR-T Cell Therapy, Other) Market Sales by Geography (USD MN)
  • Cell Therapy Market Sales by Geography (USD MN)
  • Global Market Analysis by Indication (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Infectious Diseases Market Sales by Geography (USD MN)
  • Neurological Disorders Market Sales by Geography (USD MN)
  • Rare Diseases Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112113277

The global demand for Cell And Gene Therapy CDMO Market is presumed to reach the market size of nearly USD 29.39 BN by 2030 from USD 4.05 BN in 2022 with a CAGR of 28.11% under the study period 2023 - 2030.

Cell and Gene Therapy Contract Development and Manufacturing Organizations (CDMOs) are specialized companies that provide services for the development, manufacturing, and testing of cell and gene therapies on behalf of other biopharmaceutical companies. Cell and gene therapies are advanced therapeutic approaches that involve manipulating or engineering a patient's cells to treat or prevent diseases. These therapies hold great promise for various conditions, including certain cancers, genetic disorders, and other severe illnesses.

MARKET DYNAMICS

The Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth driven by multiple factors. The increasing focus and investment in cell and gene therapies as innovative treatments for various diseases have propelled the demand for specialized manufacturing services. The complexity of the manufacturing process involved in these therapies, coupled with the need for expertise and specialized facilities, has led to a rising trend of outsourcing to CDMOs. Regulatory support and compliance are critical drivers, as the stringent regulatory requirements for cell and gene therapies make experienced CDMOs with a proven track record in adherence to standards highly sought after. Flexibility and scalability offered by CDMOs are essential factors influencing the market, enabling biopharmaceutical companies to adapt production to clinical trial progress and commercialization needs effectively. As the field of cell and gene therapy advances, the demand for CDMO services is expected to continue growing, with these organizations playing a crucial role in supporting the development and manufacturing of innovative therapies.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cell and gene therapy cdmo. The growth and trends of cell and gene therapy cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the cell and gene therapy cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Phase

  • Pre-Clinical
  • Clinical

By Product Type

  • Gene Therapy (Ex-Vivo, In-Vivo)
  • Gene-Modified Cell Therapy (Car T-Cell Therapies, Car-Nk Cell Therapy, Tcr-T Cell Therapy, Other)
  • Cell Therapy

By Indication

  • Oncology
  • Infectious Diseases
  • Neurological Disorders
  • Rare Diseases
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cell And Gene Therapy CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cell And Gene Therapy CDMO market include Lonza, Catalent, Inc, Cytiva, Samsung Biologics, Thermo Fisher Scientific Inc., Novartis AG, WuXi AppTec, AGC Biologics, OmniaBio, Rentschler Biopharma SE, Charles River Laboratories. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . CELL AND GENE THERAPY CDMO - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Phase
    • 3.7.2 Market Attractiveness Analysis By Product Type
    • 3.7.3 Market Attractiveness Analysis By Indication
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY PHASE

  • 5.1 Overview by Phase
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Phase
  • 5.4 Pre-clinical Historic and Forecast Sales by Regions
  • 5.5 Clinical Historic and Forecast Sales by Regions

6 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY PRODUCT TYPE

  • 6.1 Overview by Product Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Product Type
  • 6.4 Gene Therapy (Ex-vivo, In-vivo) Historic and Forecast Sales by Regions
  • 6.5 Gene-Modified Cell Therapy (CAR T-cell Therapies, CAR-NK Cell Therapy, TCR-T Cell Therapy, Other) Historic and Forecast Sales by Regions
  • 6.6 Cell Therapy Historic and Forecast Sales by Regions

7 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY INDICATION

  • 7.1 Overview by Indication
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Indication
  • 7.4 Oncology Historic and Forecast Sales by Regions
  • 7.5 Infectious Diseases Historic and Forecast Sales by Regions
  • 7.6 Neurological Disorders Historic and Forecast Sales by Regions
  • 7.7 Rare Diseases Historic and Forecast Sales by Regions
  • 7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE CELL AND GENE THERAPY CDMO COMPANIES

  • 9.1. Cell And Gene Therapy Cdmo Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF CELL AND GENE THERAPY CDMO INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Lonza
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. Catalent Inc
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Cytiva
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Samsung Biologics
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. Thermo Fisher Scientific Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Novartis AG
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. WuXi AppTec
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. AGC Biologics
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. OmniaBio
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. Rentschler Biopharma SE
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments
  • 10.13. Charles River Laboratories
    • 10.13.1. Company Overview
    • 10.13.2. Company Revenue
    • 10.13.3. Products
    • 10.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies